Strides Pharma Science Limited (STAR.BO)
INR 593.95
(2.87%)
INR 593.95
(2.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 6.71 Billion INR | -50.02% |
| 2022 | 13.43 Billion INR | 31.44% |
| 2021 | 10.22 Billion INR | -6.47% |
| 2020 | 10.92 Billion INR | 27.41% |
| 2019 | 8.57 Billion INR | -52.74% |
| 2018 | 18.14 Billion INR | 16.41% |
| 2017 | 15.59 Billion INR | -4.8% |
| 2016 | 16.37 Billion INR | -37.7% |
| 2015 | 26.28 Billion INR | 931.45% |
| 2014 | 2.54 Billion INR | -7.51% |
| 2013 | 2.75 Billion INR | -62.32% |
| 2012 | 7.31 Billion INR | -30.65% |
| 2011 | 10.54 Billion INR | -47.54% |
| 2010 | 20.09 Billion INR | 37.96% |
| 2009 | 14.56 Billion INR | 11.89% |
| 2008 | 13.02 Billion INR | 1.93% |
| 2007 | 12.77 Billion INR | 131.47% |
| 2006 | 5.51 Billion INR | 26.29% |
| 2005 | 4.36 Billion INR | 99.62% |
| 2004 | 2.18 Billion INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 5.77 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 6.71 Billion INR | -50.02% |
| 2023 Q4 | 6.71 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2023 Q2 | 10.53 Billion INR | 0.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 13.43 Billion INR | 31.44% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q2 | 11.19 Billion INR | 0.0% |
| 2022 Q4 | 13.43 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 FY | 10.22 Billion INR | -6.47% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 11.19 Billion INR | 0.0% |
| 2021 Q4 | 10.22 Billion INR | 0.0% |
| 2020 Q4 | 10.92 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q2 | 9.53 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 FY | 10.92 Billion INR | 27.41% |
| 2019 Q4 | 8.57 Billion INR | 0.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 8.03 Billion INR | 0.0% |
| 2019 FY | 8.57 Billion INR | -52.74% |
| 2019 Q3 | - INR | -100.0% |
| 2018 Q4 | 18.14 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 18.04 Billion INR | 0.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 FY | 18.14 Billion INR | 16.41% |
| 2017 Q4 | 15.59 Billion INR | 0.0% |
| 2017 FY | 15.59 Billion INR | -4.8% |
| 2017 Q3 | - INR | -100.0% |
| 2017 Q2 | 16.43 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q4 | 16.37 Billion INR | 0.0% |
| 2016 Q2 | 22.44 Billion INR | 0.0% |
| 2016 FY | 16.37 Billion INR | -37.7% |
| 2016 Q1 | - INR | -100.0% |
| 2015 Q4 | 26.28 Billion INR | 0.0% |
| 2015 Q3 | - INR | -100.0% |
| 2015 Q2 | 18.45 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 26.28 Billion INR | 931.45% |
| 2014 FY | 2.54 Billion INR | -7.51% |
| 2014 Q4 | 2.54 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 2.75 Billion INR | -62.32% |
| 2012 FY | 7.31 Billion INR | -30.65% |
| 2011 FY | 10.54 Billion INR | -47.54% |
| 2010 FY | 20.09 Billion INR | 37.96% |
| 2009 FY | 14.56 Billion INR | 11.89% |
| 2008 FY | 13.02 Billion INR | 1.93% |
| 2007 FY | 12.77 Billion INR | 131.47% |
| 2006 FY | 5.51 Billion INR | 26.29% |
| 2005 FY | 4.36 Billion INR | 99.62% |
| 2004 FY | 2.18 Billion INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 628.8 Million INR | -967.906% |
| Aurobindo Pharma Limited | 21.34 Billion INR | 68.547% |
| Glenmark Life Sciences Limited | 147.61 Million INR | -4449.143% |
| Granules India Limited | 689.71 Million INR | -873.596% |
| Indoco Remedies Limited | 3.51 Billion INR | -90.913% |
| Achyut Healthcare Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 235.2 Million INR | -2755.013% |
| Alkem Laboratories Limited | 400 Million INR | -1578.748% |
| Alpa Laboratories Limited | - INR | -Infinity% |
| Brooks Laboratories Limited | 3.56 Million INR | -188258.766% |
| AstraZeneca Pharma India Limited | 27.83 Million INR | -24023.401% |
| Bajaj HealthCare Limited | 650.34 Million INR | -932.527% |
| Bliss GVS Pharma Limited | 355.92 Million INR | -1786.647% |
| Dr. Reddy's Laboratories Limited | 5.99 Billion INR | -12.103% |
| Eris Lifesciences Limited | 6.54 Billion INR | -2.596% |
| FDC Limited | 2.46 Million INR | -272202.92% |
| Glenmark Pharmaceuticals Limited | 1.51 Billion INR | -342.676% |
| Gufic Biosciences Limited | 1.53 Billion INR | -336.143% |
| Ind-Swift Laboratories Limited | 111.62 Million INR | -5915.615% |
| Ipca Laboratories Limited | 5.8 Billion INR | -15.694% |
| Jagsonpal Pharmaceuticals Limited | 75.57 Million INR | -8785.788% |
| Krebs Biochemicals & Industries Limited | 1.83 Billion INR | -265.94% |
| Lasa Supergenerics Limited | - INR | -Infinity% |
| Laurus Labs Limited | 8.6 Billion INR | 21.954% |
| Lupin Limited | 1.55 Billion INR | -332.444% |
| Mankind Pharma Limited | 248.67 Million INR | -2600.286% |
| Medicamen Biotech Limited | 12.55 Million INR | -53384.588% |
| Medico Remedies Limited | 8.67 Million INR | -77333.003% |
| Megasoft Limited | 1.35 Billion INR | -394.816% |
| NATCO Pharma Limited | 53 Million INR | -12569.792% |
| Piramal Pharma Limited | 24.83 Billion INR | 72.964% |
| RPG Life Sciences Limited | -30.3 Million INR | 22261.683% |
| Sigachi Industries Limited | 265.79 Million INR | -2426.351% |
| Sun Pharmaceutical Industries Limited | 13.3 Million INR | -50388.647% |
| Suven Pharmaceuticals Limited | 212.35 Million INR | -3062.138% |
| Syncom Formulations (India) Limited | -1.21 Million INR | 550960.541% |
| Unichem Laboratories Limited | 382.22 Million INR | -1656.834% |
| Wanbury Limited | 820 Million INR | -718.901% |
| Windlas Biotech Limited | 20.18 Million INR | -33175.471% |
| ZIM Laboratories Limited | 356 Million INR | -1786.201% |
| Zydus Lifesciences Limited | 251 Million INR | -2575.295% |
| Sun Pharma Advanced Research Company Limited | 106.6 Million INR | -6199.24% |
| Divi's Laboratories Limited | 20 Million INR | -33474.95% |
| Hester Biosciences Limited | 1.81 Billion INR | -269.416% |
| Procter & Gamble Health Limited | 68.8 Million INR | -9660.16% |
| Amrutanjan Health Care Limited | 13.96 Million INR | -47974.098% |
| Bal Pharma Limited | 363.82 Million INR | -1745.67% |
| Venus Remedies Limited | 386.8 Million INR | -1636.037% |
| Aarti Pharmalabs Limited | 400 Thousand INR | -1678647.5% |
| Nectar Lifesciences Limited | 1.4 Billion INR | -378.587% |
| Shilpa Medicare Limited | 5.6 Billion INR | -19.876% |
| Aarti Drugs Limited | 2.75 Billion INR | -143.889% |
| IOL Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Suven Life Sciences Limited | - INR | -Infinity% |
| Ind-Swift Limited | 10.09 Billion INR | 33.482% |
| Valiant Laboratories Limited | 746.63 Million INR | -799.373% |
| J. B. Chemicals & Pharmaceuticals Limited | 236.4 Million INR | -2740.52% |
| Solara Active Pharma Sciences Limited | 1.05 Billion INR | -534.507% |
| Themis Medicare Limited | 267.74 Million INR | -2408.026% |
| Hikal Limited | 4.22 Billion INR | -58.803% |
| Torrent Pharmaceuticals Limited | 16.04 Billion INR | 58.136% |
| Sequent Scientific Limited | 1.42 Billion INR | -370.504% |
| Novartis India Limited | 50.7 Million INR | -13144.556% |
| Wockhardt Limited | 8.91 Billion INR | 24.635% |
| Jubilant Pharmova Limited | 31.67 Billion INR | 78.798% |
| Biofil Chemicals and Pharmaceuticals Limited | - INR | -Infinity% |
| Neuland Laboratories Limited | 449.2 Million INR | -1394.858% |
| Morepen Laboratories Limited | 33.64 Million INR | -19861.326% |
| Kilitch Drugs (India) Limited | - INR | -Infinity% |
| Mangalam Drugs & Organics Limited | 133.54 Million INR | -4928.411% |